View
comments
More than five percent of cancer patients exhibit no immune response to the two-shot COVID-19 vaccine, a new study suggests.
Researchers found that 94 percent of patients developed antibodies after receiving the Pfizer-BioNTech or Moderna shots, but six percent did not - even four weeks after the second dose.
What's more, participants who used a specific monoclonal antibody treatment within six months of vaccination did not develop antibodies.
The findings build on past research that shows some cancer patients may still be vulnerable to coronavirus after vaccination.
Researchers say the lack of an immune response is troubling because it could mean some cancer patients who are already vulnerable to the virus may be left without means to protect themselves.
A research team has found that 5% of cancer patients developed no antibody response to the COVID-19 vaccine even four weeks after receiving their second shot, leaving them vulnerable to the virus
The research team, from the Mays Cancer Center in San Antonio, Texas, and the University of Geneva in Switzerland, analyzed 131 active cancer patients that had received both shots of a two-dose mRNA vaccine.
Participants had a
